| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $5,319,665 | 19 | 100 |
| Higa Tomohiro | SVP, Finance | 0 | $0 | 3 | $5,227 | $-5,227 |
| Tingley Whittemore | Chief Medical Officer | 0 | $0 | 4 | $14,892 | $-14,892 |
| Ali Faraz | Chief Executive Officer | 0 | $0 | 4 | $32,182 | $-32,182 |
| COLUMN GROUP III GP, LP | 10 percent owner | 0 | $0 | 8 | $5.27M | $-5.27M |
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection …
Over the last 12 months, insiders at Tenaya Therapeutics, Inc. have bought $0 and sold $5.32M worth of Tenaya Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Tenaya Therapeutics, Inc. have bought $45.4M and sold $1.15M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 35,714,284 shares for transaction amount of $25M was made by GOEDDEL DAVID V () on 2025‑03‑05.
| 2026-08-17 | Sale | Ali Faraz | Chief Executive Officer | 22,232 0.0104% | $0.71 | $15,778 | -12.93% | |
| 2026-08-17 | Sale | Tingley Whittemore | Chief Medical Officer | 7,424 0.0035% | $0.71 | $5,270 | -12.93% | |
| 2026-05-18 | Sale | Ali Faraz | Chief Executive Officer | 3,390 0.0021% | $0.79 | $2,690 | -10.42% | |
| 2026-05-18 | Sale | Tingley Whittemore | Chief Medical Officer | 3,121 0.0019% | $0.79 | $2,477 | -10.42% | |
| 2026-05-18 | Sale | Higa Tomohiro | SVP, Finance | 1,485 0.0009% | $0.79 | $1,178 | -10.42% | |
| 2026-02-25 | Sale | COLUMN GROUP III GP, LP | 10 percent owner | 1.86M 1.0307% | $0.56 | $1.05M | +19.00% | |
| 2026-02-24 | Sale | COLUMN GROUP III GP, LP | 10 percent owner | 658,440 0.3977% | $0.62 | $405,138 | +16.97% | |
| 2026-02-23 | Sale | COLUMN GROUP III GP, LP | 10 percent owner | 162,291 0.0991% | $0.60 | $96,920 | +21.67% | |
| 2026-02-23 | Sale | COLUMN GROUP III GP, LP | 10 percent owner | 306,000 0.1869% | $0.60 | $182,743 | +21.67% | |
| 2026-02-20 | Sale | COLUMN GROUP III GP, LP | 10 percent owner | 277,769 0.1655% | $0.61 | $170,800 | +15.11% | |
| 2026-02-20 | Sale | COLUMN GROUP III GP, LP | 10 percent owner | 523,734 0.3121% | $0.61 | $322,044 | +15.11% | |
| 2026-02-17 | Sale | Ali Faraz | Chief Executive Officer | 14,862 0.0091% | $0.64 | $9,557 | +12.75% | |
| 2026-02-17 | Sale | Tingley Whittemore | Chief Medical Officer | 5,160 0.0032% | $0.64 | $3,319 | +12.75% | |
| 2026-02-17 | Sale | Higa Tomohiro | SVP, Finance | 3,469 0.0021% | $0.64 | $2,231 | +12.75% | |
| 2026-02-11 | Sale | COLUMN GROUP III GP, LP | 10 percent owner | 4.06M 2.4388% | $0.68 | $2.76M | +4.46% | |
| 2026-02-10 | Sale | COLUMN GROUP III GP, LP | 10 percent owner | 343,717 0.2131% | $0.82 | $280,507 | -10.13% | |
| 2025-11-17 | Sale | Ali Faraz | Chief Executive Officer | 3,126 0.002% | $1.33 | $4,158 | -42.14% | |
| 2025-11-17 | Sale | Tingley Whittemore | Chief Medical Officer | 2,877 0.0018% | $1.33 | $3,826 | -42.14% | |
| 2025-11-17 | Sale | Higa Tomohiro | SVP, Finance | 1,367 0.0009% | $1.33 | $1,818 | -42.14% | |
| 2025-08-18 | Sale | Ali Faraz | Chief Executive Officer | 14,533 0.0089% | $1.25 | $18,210 | -37.30% |
| COLUMN GROUP III GP, LP | 10 percent owner | 0 0% | $0 | 8 | 8 | +22.64% |
| GOEDDEL DAVID V | 49313559 21.6356% | $17.77M | 8 | 0 | +22.64% | |
| Casdin Eli | director | 6078860 2.667% | $2.19M | 2 | 0 | <0.0001% |
| Casdin Partners Master Fund, L.P. | 10 percent owner | 3224849 1.4149% | $1.16M | 1 | 0 | <0.0001% |
| Srivastava Deepak | director | 372435 0.1634% | $134,188.33 | 1 | 0 | +31.33% |
$9,405,928 | 107 | 12.61% | $74.85M | |
$1,701,941 | 56 | 17.58% | $93.09M | |
$66,137,559 | 49 | 6.29% | $89.66M | |
$77,146,704 | 43 | 13.28% | $93.12M | |
$909,129 | 37 | 42.19% | $67.23M |
| Increased Positions | 55 | +56.12% | 37M | +108.96% |
| Decreased Positions | 39 | -39.8% | 3M | -9.16% |
| New Positions | 25 | New | 26M | New |
| Sold Out Positions | 18 | Sold Out | 2M | Sold Out |
| Total Postitions | 114 | +16.33% | 68M | +99.8% |
| Column Group Llc | $6,909.00 | 4.33% | 9.4M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $3,723.00 | 2.33% | 5.06M | +309,530 | +6.51% | 2025-09-30 |
| Millennium Management Llc | $3,311.00 | 2.08% | 4.5M | +4M | +561.72% | 2025-09-30 |
| Blackrock, Inc. | $1,710.00 | 1.07% | 2.33M | -405,599 | -14.84% | 2025-09-30 |
| Renaissance Technologies Llc | $1,233.00 | 0.77% | 1.68M | -165,677 | -8.98% | 2025-09-30 |
| Geode Capital Management, Llc | $864.00 | 0.54% | 1.18M | -55,059 | -4.47% | 2025-09-30 |
| Euclidean Capital Llc | $747.00 | 0.47% | 1.02M | 0 | 0% | 2025-09-30 |
| Two Sigma Investments, Lp | $669.00 | 0.42% | 910,568 | +435,781 | +91.78% | 2025-09-30 |
| Aberdeen Group Plc | $442.00 | 0.28% | 600,700 | 0 | 0% | 2025-09-30 |
| Schonfeld Strategic Advisors Llc | $342.00 | 0.22% | 465,957 | +465,957 | New | 2025-09-30 |